TNFRSF13C and stroke disorder: Our findings using an anti-BAFFR monoclonal antibody indicate that specific targeting this B cell subtype is a potentially important therapeutic strategy to prevent both development and also progression of already established atherosclerotic lesions to more complex lesions that may lead to heart attacks and strokes.